SG11201508071VA - C. novyi for the treatment of solid tumors in humans - Google Patents

C. novyi for the treatment of solid tumors in humans

Info

Publication number: SG11201508071VA
Authority: SG; Singapore
Prior art keywords: novyi; humans; treatment; solid tumors; tumors
Prior art date: 2013-03-29

Application number

SG11201508071VA

Inventor

Saurabh Saha

Shibin Zhou

Bert Vogelstein

Kenneth W Kinzler

Original Assignee

Biomed Valley Discoveries Inc

Univ Johns Hopkins

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2013-03-29

Filing date

2014-03-28

Publication date

2015-10-29

2014-03-28 Application filed by Biomed Valley Discoveries Inc, Univ Johns Hopkins filed Critical Biomed Valley Discoveries Inc

2015-10-29 Publication of SG11201508071VA publication Critical patent/SG11201508071VA/en

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/66—Microorganisms or materials therefrom
- A61K35/74—Bacteria
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/66—Microorganisms or materials therefrom
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/65—Tetracyclines
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/66—Microorganisms or materials therefrom
- A61K35/74—Bacteria
- A61K35/741—Probiotics
- A61K35/742—Spore-forming bacteria, e.g. Bacillus coagulans, Bacillus subtilis, clostridium or Lactobacillus sporogenes
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61N—ELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
- A61N5/00—Radiation therapy
- A61N5/10—X-ray therapy; Gamma-ray therapy; Particle-irradiation therapy
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N1/00—Microorganisms, e.g. protozoa; Compositions thereof; Processes of propagating, maintaining or preserving microorganisms or compositions thereof; Processes of preparing or isolating a composition containing a microorganism; Culture media therefor
- C12N1/20—Bacteria; Culture media therefor
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K2035/11—Medicinal preparations comprising living procariotic cells

Landscapes

Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Chemical & Material Sciences (AREA)
General Health & Medical Sciences (AREA)
Public Health (AREA)
Animal Behavior & Ethology (AREA)
Veterinary Medicine (AREA)
Medicinal Chemistry (AREA)
Pharmacology & Pharmacy (AREA)
Organic Chemistry (AREA)
Engineering & Computer Science (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
General Chemical & Material Sciences (AREA)
Chemical Kinetics & Catalysis (AREA)
Bioinformatics & Cheminformatics (AREA)
Epidemiology (AREA)
Microbiology (AREA)
Mycology (AREA)
Immunology (AREA)
Zoology (AREA)
Biomedical Technology (AREA)
Molecular Biology (AREA)
Wood Science & Technology (AREA)
Reproductive Health (AREA)
Genetics & Genomics (AREA)
Biotechnology (AREA)
Radiology & Medical Imaging (AREA)
Pathology (AREA)
Dermatology (AREA)
Oncology (AREA)
Physical Education & Sports Medicine (AREA)
Rheumatology (AREA)
Gynecology & Obstetrics (AREA)
Pregnancy & Childbirth (AREA)
General Engineering & Computer Science (AREA)
Endocrinology (AREA)
Neurology (AREA)
Orthopedic Medicine & Surgery (AREA)
Pain & Pain Management (AREA)
Tropical Medicine & Parasitology (AREA)

SG11201508071VA 2013-03-29 2014-03-28 C. novyi for the treatment of solid tumors in humans SG11201508071VA (en)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
US201361806497P	2013-03-29	2013-03-29
PCT/US2014/032196 WO2014160950A1 (en)	2013-03-29	2014-03-28	C. novyi for the treatment of solid tumors in humans

Publications (1)

Publication Number	Publication Date
SG11201508071VA true SG11201508071VA (en)	2015-10-29

Family

ID=51625539

Family Applications (2)

Application Number	Title	Priority Date	Filing Date
SG11201508071VA SG11201508071VA (en)	2013-03-29	2014-03-28	C. novyi for the treatment of solid tumors in humans
SG10201902765VA SG10201902765VA (en)	2013-03-29	2014-03-28	C. novyi for the treatment of solid tumors in humans

Family Applications After (1)

Application Number	Title	Priority Date	Filing Date
SG10201902765VA SG10201902765VA (en)	2013-03-29	2014-03-28	C. novyi for the treatment of solid tumors in humans

Country Status (20)

Country	Link
US (3)	US10617723B2 (en)
EP (3)	EP4108248A1 (en)
JP (6)	JP6756609B2 (en)
KR (1)	KR20160021084A (en)
CN (2)	CN105451750B (en)
AU (2)	AU2014240872A1 (en)
BR (2)	BR122020006408B1 (en)
CA (2)	CA2908508C (en)
DK (1)	DK2988760T3 (en)
ES (2)	ES2922378T3 (en)
HK (1)	HK1222134A1 (en)
IL (1)	IL241823B (en)
MX (1)	MX2015013784A (en)
NZ (1)	NZ712691A (en)
PH (1)	PH12015502260A1 (en)
RU (1)	RU2718670C2 (en)
SG (2)	SG11201508071VA (en)
UA (1)	UA120036C2 (en)
WO (1)	WO2014160950A1 (en)
ZA (2)	ZA201507412B (en)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
AU2015240884B2 (en) *	2014-03-31	2020-06-18	Biomed Valley Discoveries, Inc.	Use of bacteria, bacterial products, and other immunoregulatory entities in combination with anti-CTLA-4 and/or anti-PD-1 antibodies to treat solid tumor malignancies
CN105912930B (en) *	2016-04-11	2019-02-01	北京奇虎科技有限公司	Mobile terminal and its system resource method of controlling security
WO2018039185A1 (en) *	2016-08-23	2018-03-01	Mayo Foundation For Medical Education And Research	Methods and materials for treating estrogen receptor positive breast cancer
CA3063614A1 (en) *	2017-05-16	2018-11-22	Biomed Valley Discoveries, Inc.	Compositions and methods for treating cancer with atypical braf mutations
CN109985039A (en) *	2017-12-29	2019-07-09	深圳微芯生物科技股份有限公司	For treating the combination medicine of leukaemia and its preparing the purposes in the drug for treating acute myeloid leukaemia
WO2021231611A1 (en) *	2020-05-12	2021-11-18	Splash Pharmaceuticals, Inc.	Methods for treating cancer using spl-108 polypeptide based on tp53 mutational status
US11717787B2 (en)	2021-01-04	2023-08-08	Saudi Arabian Oil Company	High free volume membrane for gas separation
CN113855710B (en) *	2021-10-09	2024-02-20	施慧达药业集团(吉林)有限公司	Application of clostridium gossypii combined tumor angiogenesis inhibitor
CN115350145A (en) *	2022-09-06	2022-11-18	华中科技大学同济医学院附属协和医院	Application of bacteria-mediated metformin-loaded polypeptide hydrogel in tumor immunotherapy

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US4599331A (en)	1984-12-24	1986-07-08	Syntex (U.S.A.) Inc.	Etianic acids as antiangiogenics
DE3680788D1 (en)	1985-10-23	1991-09-12	Upjohn Co	ANGIOSTATIC STEROIDS.
US4771042A (en)	1985-11-25	1988-09-13	The Upjohn Company	Inhibition of angiogenesis involving the coadministration of steroids with heparin or heparin fragments
EP0477195A1 (en)	1989-06-16	1992-04-01	The Upjohn Company	Suramin type compounds and angiostatic steroids to inhibit angiogenesis
ATE232540T1 (en)	1991-11-22	2003-02-15	Alcon Lab Inc	ANGIOSTATIC STEROIDS
US6905480B2 (en)	2001-02-28	2005-06-14	Rex Medical, L.P.	Apparatus for delivering ablation fluid to treat lesions
DK1446012T3 (en) *	2001-11-21	2013-10-14	Univ Johns Hopkins	BACTERYOLYTIC COMBINATION THERAPY FOR TREATMENT OF TUMORS
WO2005018332A1 (en) *	2003-08-13	2005-03-03	The General Hospital Corporation	Modified microorganisms for anti-cancer therapy
DE602004025834D1 (en)	2003-10-22	2010-04-15	Univ Johns Hopkins	THE TREATMENT OF TUMORS
US20070015738A1 (en) *	2005-07-15	2007-01-18	Walker Stephen G	Use of non-antibacterial tetracycline formulations for inhibiting bacterial spores from becoming infectious vegetative cells
TW200819540A (en) *	2006-07-11	2008-05-01	Genelux Corp	Methods and compositions for detection of microorganisms and cells and treatment of diseases and disorders
US9163091B2 (en) *	2007-05-30	2015-10-20	Lpath, Inc.	Compositions and methods for binding lysophosphatidic acid

2014
- 2014-03-28 CN CN201480028119.8A patent/CN105451750B/en active Active
- 2014-03-28 JP JP2016505594A patent/JP6756609B2/en active Active
- 2014-03-28 SG SG11201508071VA patent/SG11201508071VA/en unknown
- 2014-03-28 UA UAA201510523A patent/UA120036C2/en unknown
- 2014-03-28 EP EP22171112.0A patent/EP4108248A1/en active Pending
- 2014-03-28 ES ES20167187T patent/ES2922378T3/en active Active
- 2014-03-28 MX MX2015013784A patent/MX2015013784A/en active IP Right Grant
- 2014-03-28 NZ NZ712691A patent/NZ712691A/en unknown
- 2014-03-28 ES ES14774988T patent/ES2815564T3/en active Active
- 2014-03-28 WO PCT/US2014/032196 patent/WO2014160950A1/en active Application Filing
- 2014-03-28 US US14/781,273 patent/US10617723B2/en active Active
- 2014-03-28 EP EP14774988.1A patent/EP2988760B1/en active Active
- 2014-03-28 BR BR122020006408-0A patent/BR122020006408B1/en active IP Right Grant
- 2014-03-28 CA CA2908508A patent/CA2908508C/en active Active
- 2014-03-28 BR BR112015024621-4A patent/BR112015024621B1/en active IP Right Grant
- 2014-03-28 KR KR1020157031284A patent/KR20160021084A/en not_active Application Discontinuation
- 2014-03-28 EP EP20167187.2A patent/EP3730146B1/en active Active
- 2014-03-28 AU AU2014240872A patent/AU2014240872A1/en not_active Abandoned
- 2014-03-28 DK DK14774988.1T patent/DK2988760T3/en active
- 2014-03-28 CA CA3206655A patent/CA3206655A1/en active Pending
- 2014-03-28 RU RU2015146199A patent/RU2718670C2/en active
- 2014-03-28 SG SG10201902765VA patent/SG10201902765VA/en unknown
- 2014-03-28 CN CN202310166182.9A patent/CN116570628A/en active Pending
2015
- 2015-09-24 IL IL241823A patent/IL241823B/en active IP Right Grant
- 2015-09-29 PH PH12015502260A patent/PH12015502260A1/en unknown
- 2015-10-06 ZA ZA2015/07412A patent/ZA201507412B/en unknown
2016
- 2016-09-01 HK HK16110438.1A patent/HK1222134A1/en unknown
2017
- 2017-02-14 JP JP2017025263A patent/JP2017088619A/en active Pending
- 2017-09-21 ZA ZA2017/06402A patent/ZA201706402B/en unknown
2018
- 2018-10-26 JP JP2018201792A patent/JP2019011376A/en active Pending
2019
- 2019-01-17 AU AU2019200276A patent/AU2019200276B2/en active Active
2020
- 2020-03-31 US US16/836,003 patent/US11439669B2/en active Active
- 2020-06-25 JP JP2020109387A patent/JP7445893B2/en active Active
2021
- 2021-12-09 JP JP2021199949A patent/JP2022022392A/en active Pending
2022
- 2022-08-02 US US17/816,924 patent/US20220378852A1/en active Pending
2024
- 2024-03-06 JP JP2024034039A patent/JP2024056012A/en active Pending

Also Published As

Publication number	Publication date
MX2015013784A (en)	2016-08-08
JP2020152734A (en)	2020-09-24
JP2016515586A (en)	2016-05-30
RU2718670C2 (en)	2020-04-13
CA2908508A1 (en)	2014-10-02
BR112015024621A8 (en)	2019-12-10
CN116570628A (en)	2023-08-11
EP3730146A1 (en)	2020-10-28
CA2908508C (en)	2023-09-19
CN105451750B (en)	2023-03-10
US11439669B2 (en)	2022-09-13
EP2988760A4 (en)	2016-10-05
ZA201706402B (en)	2019-01-30
AU2019200276B2 (en)	2020-06-11
US20220378852A1 (en)	2022-12-01
BR112015024621A2 (en)	2017-07-18
US20160051597A1 (en)	2016-02-25
NZ712691A (en)	2020-01-31
JP2017088619A (en)	2017-05-25
JP2024056012A (en)	2024-04-19
EP2988760A1 (en)	2016-03-02
KR20160021084A (en)	2016-02-24
UA120036C2 (en)	2019-09-25
ES2922378T3 (en)	2022-09-14
IL241823B (en)	2021-02-28
US10617723B2 (en)	2020-04-14
JP2019011376A (en)	2019-01-24
HK1222134A1 (en)	2017-06-23
US20200330525A1 (en)	2020-10-22
JP7445893B2 (en)	2024-03-08
ES2815564T3 (en)	2021-03-30
CA3206655A1 (en)	2014-10-02
ZA201507412B (en)	2018-05-30
WO2014160950A1 (en)	2014-10-02
SG10201902765VA (en)	2019-04-29
AU2019200276A1 (en)	2019-02-07
AU2014240872A1 (en)	2015-10-22
BR112015024621B1 (en)	2021-09-28
RU2015146199A (en)	2017-05-10
RU2020111670A (en)	2020-04-13
EP2988760B1 (en)	2020-06-17
BR122020006408B1 (en)	2021-09-28
EP3730146B1 (en)	2022-05-04
DK2988760T3 (en)	2020-07-13
EP4108248A1 (en)	2022-12-28
PH12015502260A1 (en)	2016-02-01
JP2022022392A (en)	2022-02-03
JP6756609B2 (en)	2020-09-16
CN105451750A (en)	2016-03-30

Publication	Publication Date	Title
IL273090B (en)	2022-06-01	Methods and compositions for the treatment of cancer
EP3027192A4 (en)	2017-03-22	Methods for the treatment of solid tumors
IL243976A0 (en)	2016-04-21	Kdm1a inhibitors for the treatment of disease
SI3033086T1 (en)	2022-01-31	Combination therapy for the treatment of cancer
HK1221408A1 (en)	2017-06-02	Combination therapy for the treatment of glioblastoma
ZA201706402B (en)	2019-01-30	C.novyi for the treatment of solid tumors in humans
EP3033079A4 (en)	2017-04-05	Methods for the treatment of her2 amplified cancer
HK1220324A1 (en)	2017-05-05	Methods, compounds, and compositions for the treatment of angiotensin-related diseases
IL248767B (en)	2021-08-31	Trimethoxyphenyl-benzimidazole compound for use in the treatment of cancer
EP3007756A4 (en)	2017-02-22	Catheter-assisted tumor treatment
PT3511004T (en)	2024-09-03	Combined preparations for the treatment of cancer
HK1222548A1 (en)	2017-07-07	Pharmaceutical combinations for the treatment of cancer
HK1223547A1 (en)	2017-08-04	Methods for the treatment of cancer
EP3089745A4 (en)	2017-05-17	Compounds, compositions, and methods for the treatment of cancers
LT2984108T (en)	2017-11-10	Anti-s100a7 antibodies for the treatment and diagnosis of cancer
EP3016948B8 (en)	2017-07-19	2-acylaminothiazoles for the treatment of cancer
EP3013332A4 (en)	2017-05-31	Cancer treatment
GB201300546D0 (en)	2013-02-27	Cancer Treatment